Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders

Drugs & Aging
J E Frampton, R N Brogden

Abstract

Pentoxifylline (oxpentifylline) has been used widely in the treatment of intermittent claudication, a prevalent condition in the elderly population. The exact mechanism(s) of action of the drug are unclear, but may be related to identified effects on white blood cell function and haemorrheological parameters. Clinical trials which conform best with European and North American guidelines have shown that 6 months' oral therapy with pentoxifylline 1200 mg/day significantly improves walking distances in patients with intermittent claudication. Patients most likely to benefit from treatment are those with an ankle/arm blood pressure ratio < or = 0.8 and a history of disease > 1 year. However, it remains unclear whether pentoxifylline or any other conservative treatment approach (including physical training) offers long term benefit, as studies comparing the development of intermittent claudication after several years of treatment with the natural course of the disease are still lacking. In patients with more severe vascular disease, intravenous administration of pentoxifylline (1200 mg/day for 21 days) decreased rest pain in patients with critical limb ischaemia. Oral administration (1200 g/day for up to 6 months) increased the heal...Continue Reading

Citations

Nov 30, 2002·Phytotherapy Research : PTR·Nongluck SookvanichsilpPirin Yuennan
Mar 7, 2003·Alzheimer Disease and Associated Disorders·Michael C Sha, Christopher M Callahan
Aug 9, 2008·Digestive Diseases and Sciences·Mehmet GülAli Otlu
Jan 23, 2009·The Cochrane Database of Systematic Reviews·Scott G Fraser, Wendy Adams
Mar 1, 2012·European Journal of Clinical Pharmacology·Suzana Mimica Matanović, Vera Vlahovic-Palcevski
Jun 18, 2015·Clinical Pharmacology and Therapeutics·P-C WuUNKNOWN Kidney Consortium
Feb 26, 2004·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·A Kursat BozkurtMeltem Ercan
Feb 20, 2002·Clinical Neuropharmacology·Beata HorvathKalman Toth
May 19, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Joseph FrancisRobert B Felder
Nov 8, 2013·BioMed Research International·Mohammad Zahid KamranRajiv P Gude
Mar 18, 2020·European Journal of Pediatrics·Serife KurulH Rob Taal
Jan 24, 2007·Diseases of the Colon and Rectum·Pablo Parra-MembrivesVirginia Méndez-García
Jun 26, 2008·Antioxidants & Redox Signaling·Agnieszka LobodaJozef Dulak
Jun 19, 2012·The Korean Journal of Internal Medicine·Hui-Kyoung SunSang-Youb Han
Dec 22, 1998·The American Journal of Gastroenterology·E EleftheriadisD Koufogiannis
May 2, 2013·The Cochrane Database of Systematic Reviews·Lindsay Robertson, Alina Andras
Jun 12, 1999·International Journal of Experimental Pathology·O ArrietaJ Sotelo
Jan 20, 2012·The Cochrane Database of Systematic Reviews·Donghao LuGang Shi
Oct 8, 1999·Vascular Medicine·M Davis, D Barer
Oct 17, 2020·The Cochrane Database of Systematic Reviews·Cathryn BroderickKareem Salhiyyah
Mar 21, 2006·European Journal of Pharmacology·Marianna FantinCsaba Vizler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.